INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $110,763 | -40.8% | 26,372 | -21.5% | 0.00% | – |
| Q2 2023 | $187,069 | +68.7% | 33,585 | +73.5% | 0.00% | – |
| Q1 2023 | $110,909 | +703.5% | 19,356 | +47.2% | 0.00% | – |
| Q4 2022 | $13,803 | -76.6% | 13,146 | -41.0% | 0.00% | – |
| Q3 2022 | $59,000 | -70.1% | 22,284 | -45.9% | 0.00% | – |
| Q2 2022 | $197,000 | +207.8% | 41,174 | +158.4% | 0.00% | – |
| Q1 2022 | $64,000 | -51.9% | 15,937 | -18.0% | 0.00% | – |
| Q4 2021 | $133,000 | -36.4% | 19,440 | +8.0% | 0.00% | – |
| Q3 2021 | $209,000 | -71.3% | 17,994 | -57.9% | 0.00% | – |
| Q2 2021 | $728,000 | +49.8% | 42,754 | +74.2% | 0.00% | – |
| Q1 2021 | $486,000 | +20.0% | 24,550 | +24.9% | 0.00% | – |
| Q4 2020 | $405,000 | +1127.3% | 19,653 | +1471.0% | 0.00% | – |
| Q3 2020 | $33,000 | – | 1,251 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $10,852,000 | 4.54% |
| CHI Advisors LLC | 892,057 | $6,084,000 | 2.02% |
| Sofinnova Investments, Inc. | 2,028,308 | $13,833,000 | 0.81% |
| MPM BioImpact LLC | 302,615 | $2,064,000 | 0.38% |
| NEA Management Company, LLC | 2,444,379 | $16,671,000 | 0.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $15,991,000 | 0.34% |
| Rock Springs Capital Management LP | 868,466 | $5,923,000 | 0.14% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,013,216 | $6,910,000 | 0.13% |
| Orbimed Advisors | 526,600 | $3,591,000 | 0.05% |
| Overbrook Management Corp | 16,726 | $114,000 | 0.02% |